343 related articles for article (PubMed ID: 25015994)
1. A multianalyte PCR blood test outperforms single analyte ELISAs (chromogranin A, pancreastatin, neurokinin A) for neuroendocrine tumor detection.
Modlin IM; Drozdov I; Alaimo D; Callahan S; Teixiera N; Bodei L; Kidd M
Endocr Relat Cancer; 2014 Aug; 21(4):615-28. PubMed ID: 25015994
[TBL] [Abstract][Full Text] [Related]
2. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
[TBL] [Abstract][Full Text] [Related]
3. Serum pancreastatin: the next predictive neuroendocrine tumor marker.
Rustagi S; Warner RR; Divino CM
J Surg Oncol; 2013 Aug; 108(2):126-8. PubMed ID: 23775817
[TBL] [Abstract][Full Text] [Related]
4. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
[TBL] [Abstract][Full Text] [Related]
5. Blood measurement of neuroendocrine gene transcripts defines the effectiveness of operative resection and ablation strategies.
Modlin IM; Frilling A; Salem RR; Alaimo D; Drymousis P; Wasan HS; Callahan S; Faiz O; Weng L; Teixeira N; Bodei L; Drozdov I; Kidd M
Surgery; 2016 Jan; 159(1):336-47. PubMed ID: 26456125
[TBL] [Abstract][Full Text] [Related]
6. Neuroendocrine tumours of the small bowel: interpretation of raised circulating chromogranin A, urinary 5 hydroxy indole acetic acid and circulating neurokinin A.
Ardill JE; Armstrong L; Smye M; Doherty R; McCance DR; Johnston BT
QJM; 2016 Feb; 109(2):111-5. PubMed ID: 25979268
[TBL] [Abstract][Full Text] [Related]
7. A PCR blood test outperforms chromogranin A in carcinoid detection and is unaffected by proton pump inhibitors.
Modlin IM; Aslanian H; Bodei L; Drozdov I; Kidd M
Endocr Connect; 2014 Dec; 3(4):215-23. PubMed ID: 25316294
[TBL] [Abstract][Full Text] [Related]
8. Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis.
Kidd M; Drozdov IA; Matar S; Gurunlian N; Ferranti NJ; Malczewska A; Bennett P; Bodei L; Modlin IM
PLoS One; 2019; 14(6):e0218592. PubMed ID: 31247038
[TBL] [Abstract][Full Text] [Related]
9. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
[TBL] [Abstract][Full Text] [Related]
10. Circulating Transcript Analysis (NETest) in GEP-NETs Treated With Somatostatin Analogs Defines Therapy.
Ćwikła JB; Bodei L; Kolasinska-Ćwikła A; Sankowski A; Modlin IM; Kidd M
J Clin Endocrinol Metab; 2015 Nov; 100(11):E1437-45. PubMed ID: 26348352
[TBL] [Abstract][Full Text] [Related]
11. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
12. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors.
Bodei L; Kidd M; Modlin IM; Severi S; Drozdov I; Nicolini S; Kwekkeboom DJ; Krenning EP; Baum RP; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):839-851. PubMed ID: 26596723
[TBL] [Abstract][Full Text] [Related]
13. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
[TBL] [Abstract][Full Text] [Related]
14. Chromogranin A as a marker of neuroendocrine neoplasia: an Italian Multicenter Study.
Zatelli MC; Torta M; Leon A; Ambrosio MR; Gion M; Tomassetti P; De Braud F; Delle Fave G; Dogliotti L; degli Uberti EC;
Endocr Relat Cancer; 2007 Jun; 14(2):473-82. PubMed ID: 17639060
[TBL] [Abstract][Full Text] [Related]
15. Chromogranin A: any relevance in neuroendocrine tumors?
Kidd M; Bodei L; Modlin IM
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):28-37. PubMed ID: 26627724
[TBL] [Abstract][Full Text] [Related]
16. Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve follow-up after curative surgical resection of well-differentiated pancreatic neuroendocrine tumors.
Genç CG; Jilesen APJ; Nieveen van Dijkum EJM; Klümpen HJ; van Eijck CHJ; Drozdov I; Malczewska A; Kidd M; Modlin I
J Surg Oncol; 2018 Jul; 118(1):37-48. PubMed ID: 30114319
[TBL] [Abstract][Full Text] [Related]
17. Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina.
Belli SH; Oneto A; Aranda C; O'Connor JM; Domenichini E; Roca E; Méndez G; Bestani MC; Parma P; Giacomi N; Marmissolle F
Acta Gastroenterol Latinoam; 2009 Sep; 39(3):184-9. PubMed ID: 19845257
[TBL] [Abstract][Full Text] [Related]
18. [The diagnostic value of plasma chromogranin A in neuroendocrine tumors].
Yang XO; Li JN; Qian JM; Yang H; Chen Q; Lu L
Zhonghua Nei Ke Za Zhi; 2011 Feb; 50(2):124-7. PubMed ID: 21418832
[TBL] [Abstract][Full Text] [Related]
19. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
20. Blood Transcript Profiling for the Detection of Neuroendocrine Tumors: Results of a Large Independent Validation Study.
van Treijen MJC; Korse CM; van Leeuwaarde RS; Saveur LJ; Vriens MR; Verbeek WHM; Tesselaar MET; Valk GD
Front Endocrinol (Lausanne); 2018; 9():740. PubMed ID: 30564197
[No Abstract] [Full Text] [Related]
[Next] [New Search]
